Drug Trial Radar · NCT07082842
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
472
Planned (sponsor's estimate)
Start
Oct 27, 2025
Primary completion
Jan 15, 2031
Study completion Feb 15, 2032
Sponsor
- Lead sponsor
- Sunshine Lake Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A multicenter, parallel, randomized, placebo (double-blind) and pirfenidone (open-label) controlled Phase III clinical trial to evaluate the efficacy and safety of HEC585 in patients with idiopathic pulmonary fibrosis (IPF)
Conditions
- Idiopathic Pulmonary Fibrosis (IPF)
Interventions
HEC585Drug
HEC585 tablet, taken once daily
PlaceboDrug
HEC585 Simulation Board, taken once daily
PirfenidoneDrug
Pirfenidone, taken three times a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in FVC from baseline at 52 weeks (mL)Time frame: 52week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.